Whats new

Whats new.

goetzpartners securities - Door re-opens to first eftilagimod alpha approval

December 15th 2020

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

Go back